August 19, 2024

1 Minute
Medicine

AstraZeneca and Daiichi Sankyo Receives Chinese Approval for Gastric Cancer Therapy

AstraZeneca and Daiichi Sankyo have announced that the duo’s antibody-drug conjugate (ADC), Enhertu (trastuzumab deruxtecan), has received conditional approval from the China National Medical Products Administration (NMPA) for gastric cancer. Now, Enhertu can be used as...
Read More